Xtant Medical Buys Production Operations for nanOss Products from RTI Surgical Following Product Acquisition
Xtant Medical Holdings has announced the acquisition of nanOss production operations from RTI Surgical. nanOss consists of a product line of bioactive bone void fillers.
With this acquisition, Xtant gains access to assets, including equipment and inventory used in RTI’s synthetic bone graft business. In addition, the medical technology company assumes the lease for the nanOss production facility located in Greenville, North Carolina.
Xtant paid a purchase price of $2 million in cash and contingent payments are to be based on the future sales of next-generation nanOss products. This agreement follows Xtant’s previous acquisition of nanOss distribution rights and intellectual property. These assets became part of the company’s holdings through the acquisition of Surgalign’s assets related to its biologics and spinal fixation business in August 2023. The transaction was done under a bankruptcy court supervised process for $5 million and assumed liabilities.
CEO of Xtant Medical, Sean Browne, emphasized the significance of the nanOss acquisition in the context of the company’s larger orthobiologics strategy. He stated, “nanOss is an important part of our total orthobiologics offering, and having full control over this product line enables us to begin the process of reviving and growing it.”